U.S. regulators are poised to tap the brakes on approving dozens of cancer drugs and other new medicines developed in China.
The regulators have expressed concerns about the quality of studies largely conducted in China and whether the results can apply to patients in the U.S.
The shift threatens to halt the plans of Western drugmakers, including...
. . .
This article originally appears at Wall Street Journal. To read the full article, click here.